Creso Pharma

Creso Pharma carries a Neutral rating, with a composite score of 40 out of 100 and a conviction reading of 3 of 5. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the regulatory pillar at 56, and pulls the composite toward the lower edge of the band. Editorial lags at 30, softening what would otherwise be a stronger reading.

The scoring inputs are concrete: reported revenue growth of 43.6 percent year over year, an operating margin of -216.9 percent. Together they explain most of the pillar mix. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Creso Pharma can be compared against the global cannabis coverage universe on identical inputs, refreshed on the ingest cycle.

The rating turns on regulatory pace. Filings landing at above the trailing-90-day cadence, combined with an unblemished enforcement record, would carry Creso Pharma above the Neutral anchor; a lull would soften the read.